Litcius/Paper detail

Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic

Jonathan Cantor, Andrew W. Dick, Rebecca L. Haffajee, Megan F. Pera, Dena M Bravata, Bradley D. Stein, Christopher Whaley

2021Journal of Substance Abuse Treatment19 citationsDOIOpen Access PDF

Topics & Concepts

BuprenorphineCoronavirus disease 2019 (COVID-19)Pandemic2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Health insuranceBusinessPsychologyVirologyMedicinePolitical scienceLawHealth careInternal medicineDiseaseInfectious disease (medical specialty)ReceptorOutbreakOpioidOpioid Use Disorder TreatmentHIV, Drug Use, Sexual RiskSuicide and Self-Harm Studies
Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic | Litcius